Orion - Company Announcement

Orion Diagnostica proposes co-operation negotiations on streamlining its operations and reducing no more than 80 employees in Finland

ORION CORPORATION        STOCK EXCHANGE RELEASE 10 APRIL 2013 at 08.55 EEST



Orion Diagnostica Oy, a subsidiary of Orion Corporation focusing on diagnostic
tests, has today given a negotiation proposal, as laid down in the Finnish Act
on Co-operation within Undertakings, on streamlining operations, reorganizing
production and possible personnel reductions. The estimate on the reduction need
is no more than 80 employees. The measures considered by the employer aim to
streamline operations and improve the company's profitability among other things
by simplifying the product portfolio. With the considered measures Orion
Diagnostica aims to ensure the continuity of operations and competitiveness also
in the future.


The negotiations concern all Orion Diagnostica's personnel, except some minor
exclusions, in all personnel groups in all sites in Finland. In addition to
other measures, the employer is considering closing down Orion Diagnostica's
Turku site. Possible reorganization of the operations is estimated to cause
changes in roles and responsibilities, lead to transfers of employees to other
positions or other sites, changes to the terms of employment as well as possible
terminations of employment by notice. Should redundancies occur, the employer
would, according to a preliminary estimate, give notice during 2013.



Orion Corporation



 Timo Lappalainen  Olli Huotari
 President and CEO SVP, Corporate Functions




Contact person:
Timo Lappalainen, President and CEO
tel. +358 10 426 3692



Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi


Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. Pharmaceutical R&D focuses on central nervous system drugs,
oncology and critical care drugs, and Easyhaler® pulmonary drugs.

Orion's net sales in 2012 amounted to EUR 980 million and the company had about
3,500 employees. Orion's A and B shares are listed on NASDAQ OMX Helsinki.

[HUG#1691790]